valsartan has been researched along with (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid in 25 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 8 (32.00) | 29.6817 |
| 2010's | 16 (64.00) | 24.3611 |
| 2020's | 1 (4.00) | 2.80 |
| Authors | Studies |
|---|---|
| Aviram, M; Hussein, O; Rosenblat, M; Shneider, J | 1 |
| Cui, TX; Horiuchi, M; Iwai, M; Li, JM; Li, Z; Nakagami, H | 1 |
| Chen, R; Cui, TX; Gao, XY; Horiuchi, M; Iwai, M; Jinno, T; Li, Z; Liu, HW; Okumura, M; Suzuki, J; Tsuda, M; Wu, L | 1 |
| Chu, GL; Ding, GH; Gao, P; Jia, RH; Liu, HY; Song, EF; Yang, DP | 1 |
| Li, JX; Li, QZ; Liu, L; Zhao, SP; Zhou, HN | 1 |
| Balakhonova, TV; Chernova, NA; Fomicheva, OA; Karpov, IuA; Kuznetsova, TV; Masenko, VP; Pogorelova, OA; Rogoza, AN; Soboleva, GN | 1 |
| Alonso, RM; Ferreirós, N; Gonzalez, O; Iriarte, G; Jiménez, RM; Maguregui, MI | 1 |
| Chen, FM; Fu, GS; Wang, H; Wang, YJ | 1 |
| Battaglia, G; Cambareri, F; Carminati, S; Cravedi, P; David, S; Ene-Iordache, B; Gaspari, F; Granata, A; Ledda, F; Loriga, G; Motterlini, N; Perna, A; Remuzzi, G; Rota, S; Rubis, N; Ruggenenti, P; Satta, A; Stucchi, N; Tonelli, M | 1 |
| Dejima, T; Fujikawa, T; Haku, S; Kanaoka, T; Kondoh, S; Konno, Y; Maeda, A; Mitsuhashi, H; Mizushima, S; Moriya, T; Ogawa, N; Ohsawa, M; Okano, Y; Ozawa, M; Suzuki, D; Tamura, K; Tanaka, K; Toyoda, M; Umemura, S; Umezono, T; Wakui, H; Yamakawa, T; Yanagi, M | 1 |
| Janić, M; Jug, B; Lunder, M; Sabovič, M | 1 |
| Boncelj, M; Eržen, B; Janež, A; Janić, M; Kanc, K; Lunder, M; Šabović, M; Savić, V | 1 |
| Janić, M; Lunder, M; Šabovič, M | 1 |
| Alpa, M; Cravedi, P; Daina, E; Gamba, S; Gaspari, F; Perna, A; Remuzzi, G; Roccatello, D; Ruggenenti, P | 1 |
| Cerkovnik, P; Janić, M; Lunder, M; Novaković, S; Prosenc Zmrzljak, U; Šabovič, M | 1 |
| Li, GP; Li, LF; Liang, YZ; Liu, T; Qi, WW; Xu, G; Ye, L | 1 |
| Boncelj Svetek, M; Eržen, B; Kanc, K; Šabovič, M | 1 |
| Janež, A; Janić, M; Kanc, K; Lunder, M; Šabovič, M; Savić, V | 1 |
| Černe, D; Drevenšek, G; France Štiglic, A; Janić, M; Jerin, A; Lunder, M; Marc, J; Šabovič, M; Skitek, M | 1 |
| Apola, A; Kwiecień, A; Maślanka, A; Opoka, W; Stolarczyk, M | 1 |
| Eržen, B; Janić, M; Novaković, S; Šabovič, M; Škerl, P; Turk Veselič, M; Žorž, N | 1 |
| Eržen, B; Hanžel, J; Piletič, Ž; Šabovič, M; Turk Veselič, M | 1 |
| Dong, Z; Li, G; Li, L; Liang, Y; Liu, E; Liu, T; Niu, X; Qi, W; Zhao, Z | 1 |
| Janić, M; Lunder, M; Novaković, S; Šabovič, M; Škerl, P | 1 |
| Dong, Z; Li, G; Li, L; Liang, Y; Liu, E; Liu, T; Niu, X; Wang, J; Yang, Y; Zhao, Z | 1 |
1 review(s) available for valsartan and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
A low-dose combination of fluvastatin and valsartan: a new "drug" and a new approach for decreasing the arterial age.
Topics: Aging; Animals; Antioxidants; Arteries; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Combinations; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; Valsartan; Vascular Stiffness | 2015 |
12 trial(s) available for valsartan and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Effect of fluvastatin and valsartan, alone and in combination, on postprandial vascular inflammation and fibrinolytic activity in patients with essential hypertension.
Topics: Aged; Antihypertensive Agents; Blood Pressure; Dietary Fats; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fibrinolysis; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Lipids; Male; Middle Aged; P-Selectin; Plasminogen Activator Inhibitor 1; Postprandial Period; Tetrazoles; Tissue Plasminogen Activator; Valine; Valsartan; Vasculitis | 2007 |
[Influence of valsartan, fluvastatin extended release and their combination on arterial pressure, parameters of lipid metabolism, and endothelial function in patients with hypertensive disease].
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Cholesterol; Delayed-Action Preparations; Endothelium, Vascular; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Male; Middle Aged; Prospective Studies; Tetrazoles; Valine; Valsartan | 2007 |
Effects of add-on fluvastatin therapy in patients with chronic proteinuric nephropathy on dual renin-angiotensin system blockade: the ESPLANADE trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Blood Pressure; Chi-Square Distribution; Chronic Disease; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Italy; Kidney Diseases; Lipids; Male; Middle Aged; Prospective Studies; Proteinuria; Renin-Angiotensin System; Tetrazoles; Time Factors; Treatment Outcome; Valine; Valsartan | 2010 |
The effects of low-dose fluvastatin and valsartan combination on arterial function: a randomized clinical trial.
Topics: Adult; Aging; Angiotensin II Type 1 Receptor Blockers; Atherosclerosis; Blood Flow Velocity; Brachial Artery; Carotid Arteries; Dose-Response Relationship, Drug; Drug Therapy, Combination; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pulsatile Flow; Tetrazoles; Valine; Valsartan; Vascular Stiffness | 2012 |
Low-Dose Fluvastatin and Valsartan Rejuvenate the Arterial Wall Through Telomerase Activity Increase in Middle-Aged Men.
Topics: Arteries; Dose-Response Relationship, Drug; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; Inflammation; Leukocytes; Linear Models; Male; Middle Aged; Oxidative Stress; Rejuvenation; Telomerase; Valsartan | 2016 |
Upstream therapeutic strategies of Valsartan and Fluvastatin on Hypertensive patients with non-permanent Atrial Fibrillation (VF-HT-AF): study protocol for a randomized controlled trial.
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Atrial Fibrillation; Blood Pressure; China; Clinical Protocols; Electrocardiography, Ambulatory; Fatty Acids, Monounsaturated; Fluvastatin; Heart Failure; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Indoles; Myocardial Infarction; Prospective Studies; Recurrence; Research Design; Risk Assessment; Risk Factors; Shock, Cardiogenic; Time Factors; Treatment Outcome; Valsartan | 2015 |
Impaired endothelial function and arterial stiffness in patients with type 2 diabetes - The effect of a very low-dose combination of fluvastatin and valsartan.
Topics: Angiotensin II Type 1 Receptor Blockers; Arteries; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Endothelium, Vascular; Fatty Acids, Monounsaturated; Fluvastatin; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Middle Aged; Pulse Wave Analysis; Ultrasonography; Valsartan; Vascular Stiffness; Vasodilation | 2017 |
Improvement of arterial wall phenotype in subjects at moderate cardiovascular risk induced by very low-dose fluvastatin/valsartan combination: a pilot study.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Arteries; Biomarkers; Cardiovascular Diseases; Double-Blind Method; Drug Combinations; Fluvastatin; Gene Expression Regulation; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Phenotype; Pilot Projects; Risk Factors; Slovenia; Time Factors; Treatment Outcome; Valsartan; Vascular Stiffness; Vasodilation | 2018 |
Improving Arterial Wall Characteristics in Patients After Myocardial Infarction with a Very Low Dose of Fluvastatin and Valsartan: A Proof-of-Concept Study.
Topics: Blood Flow Velocity; Brachial Artery; Carotid Arteries; Double-Blind Method; Drug Therapy, Combination; Endothelium, Vascular; Fluvastatin; Humans; Male; Middle Aged; Myocardial Infarction; Pilot Projects; Valsartan; Vascular Stiffness | 2018 |
Upstream therapeutic strategies of valsartan and fluvastatin on hypertensive patients with non-permanent atrial fibrillation.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Anti-Arrhythmia Agents; Antihypertensive Agents; Atrial Fibrillation; Blood Pressure; China; Disease Progression; Female; Fluvastatin; Heart Rate; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Incidence; Male; Middle Aged; Prospective Studies; Recurrence; Time Factors; Treatment Outcome; Valsartan | 2018 |
Expression of Longevity Genes Induced by a Low-Dose Fluvastatin and Valsartan Combination with the Potential to Prevent/Treat "Aging-Related Disorders".
Topics: Adult; Aging; AMP-Activated Protein Kinases; Angiotensin II Type 1 Receptor Blockers; Dose-Response Relationship, Drug; Female; Fluvastatin; Gene Expression; Glucuronidase; Humans; Klotho Proteins; Longevity; Male; Middle Aged; Neurodegenerative Diseases; Placebo Effect; Sirtuin 1; Telomerase; Valsartan | 2019 |
Combined treatment with valsartan and fluvastatin to delay disease progression in nonpermanent atrial fibrillation with hypertension: A clinical trial.
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Atrial Fibrillation; Blood Pressure; Disease Progression; Drug Therapy, Combination; Female; Fluvastatin; Heart Rate; Humans; Hypertension; Male; Middle Aged; Retrospective Studies; Treatment Outcome; Valsartan | 2020 |
12 other study(ies) available for valsartan and (3S,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid
| Article | Year |
|---|---|
Valsartan therapy has additive anti-oxidative effect to that of fluvastatin therapy against low-density lipoprotein oxidation: studies in hypercholesterolemic and hypertensive patients.
Topics: Analysis of Variance; Antioxidants; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Hypercholesterolemia; Hypertension; Indoles; Lipoproteins, LDL; Oxidation-Reduction; Tetrazoles; Valine; Valsartan | 2002 |
Fluvastatin enhances the inhibitory effects of a selective angiotensin II type 1 receptor blocker, valsartan, on vascular neointimal formation.
Topics: Angiotensin Receptor Antagonists; Animals; Arterial Occlusive Diseases; Cell Division; Cells, Cultured; DNA; DNA-Binding Proteins; Drug Synergism; Fatty Acids, Monounsaturated; Fluvastatin; Genes, fos; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Muscle, Smooth, Vascular; Phosphorylation; Receptor, Angiotensin, Type 1; Signal Transduction; Tetrazoles; Valine; Valsartan | 2003 |
Fluvastatin enhances the inhibitory effects of a selective AT1 receptor blocker, valsartan, on atherosclerosis.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Apolipoproteins E; Arteriosclerosis; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Male; Mice; Mice, Knockout; Oxidative Stress; Tetrazoles; Valine; Valsartan | 2004 |
Renoprotective effect of combining angiotensin II receptor blockers and statins in diabetic rats.
Topics: Animals; Chemokine CCL2; Diabetes Mellitus, Experimental; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Fluvastatin; Indoles; Kidney; Male; NF-kappa B; Rats; Rats, Sprague-Dawley; RNA, Messenger; Tetrazoles; Transcription Factor RelA; Valine; Valsartan | 2005 |
Validation of a fast liquid chromatography-UV method for the analysis of drugs used in combined cardiovascular therapy in human plasma.
Topics: Cardiovascular Agents; Chlorthalidone; Chromatography, Liquid; Drug Stability; Fatty Acids, Monounsaturated; Fluvastatin; Humans; Indoles; Linear Models; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry, Ultraviolet; Tetrazoles; Time Factors; Valine; Valsartan | 2009 |
[The effect of valsartan and fluvastatin on the connective tissue growth factor expression in experimental diabetic cardiomyopathy].
Topics: Animals; Cardiomyopathies; Connective Tissue; Connective Tissue Growth Factor; Diabetes Mellitus, Experimental; Fatty Acids, Monounsaturated; Fluvastatin; Indoles; Male; Rats; Rats, Sprague-Dawley; Tetrazoles; Valine; Valsartan | 2009 |
Effects of multiple factorial intervention on ambulatory BP profile and renal function in hypertensive type 2 diabetic patients with overt nephropathy - a pilot study.
Topics: Albuminuria; Anticholesteremic Agents; Antihypertensive Agents; Blood Glucose; Blood Pressure; Blood Pressure Monitoring, Ambulatory; Circadian Rhythm; Comorbidity; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Fatty Acids, Monounsaturated; Female; Fluvastatin; Glomerular Filtration Rate; Heart Rate; Humans; Hypertension; Indoles; Kidney; Lipids; Male; Middle Aged; Pilot Projects; Prospective Studies; Regression Analysis; Tetrazoles; Valine; Valsartan | 2011 |
Improvement of arterial wall characteristics by the low-dose fluvastatin and valsartan combination in type 1 diabetes mellitus patients.
Topics: Adult; Angiotensin II Type 1 Receptor Blockers; Anticholesteremic Agents; Blood Pressure; Carotid Arteries; Diabetes Mellitus, Type 1; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Indoles; Male; Middle Aged; Tetrazoles; Treatment Outcome; Valine; Valsartan | 2013 |
A multidrug, antiproteinuric approach to alport syndrome: a ten-year cohort study.
Topics: Adult; Aged; Albuminuria; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Benzazepines; Calcium Channel Blockers; Cohort Studies; Diltiazem; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Follow-Up Studies; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Kidney Function Tests; Male; Middle Aged; Nephritis, Hereditary; Prospective Studies; Proteinuria; Valsartan | 2015 |
Very low-dose fluvastatin-valsartan combination decreases parameters of inflammation and oxidative stress in patients with type 1 diabetes mellitus.
Topics: Adult; Diabetes Mellitus, Type 1; Double-Blind Method; Fatty Acids, Monounsaturated; Female; Fluvastatin; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Inflammation; Male; Oxidative Stress; Valsartan | 2017 |
Sub-therapeutic doses of fluvastatin and valsartan are more effective than therapeutic doses in providing beneficial cardiovascular pleiotropic effects in rats: A proof of concept study.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Aorta, Thoracic; Arginine; Blood Pressure; Cholesterol; Coronary Circulation; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Fatty Acids, Monounsaturated; Female; Fluvastatin; Heart; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Indoles; Male; Myocardial Reperfusion Injury; Myocardium; Nitric Oxide; Nitric Oxide Synthase Type III; Rats, Wistar; Receptor, Endothelin A; Time Factors; Valsartan; Vasodilation | 2017 |
Spectrophotometric method for simultaneous determination of valsartan and substances from the group of statins in binary mixtures.
Topics: Atorvastatin; Fatty Acids, Monounsaturated; Fluvastatin; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Indoles; Pravastatin; Reproducibility of Results; Sensitivity and Specificity; Spectrophotometry; Valsartan | 2017 |